Morvesin (Tamsulosin Hydrochloride)

Tamsulosin Hydrochloride, the active ingredient in Morvesin, is a Alpha‑1 adrenergic antagonist presented as a [strength]/[form] for oral use. It treats benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms in adult men.

GNH USA supplies Morvesin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Morvesin, an alpha‑1 adrenergic antagonist, is used to manage conditions related to prostate enlargement and urinary flow obstruction.

- Benign prostatic hyperplasia (BPH): improves urinary flow and reduces bladder outlet obstruction. - Lower urinary tract symptoms associated with BPH: alleviates urgency, frequency, and nocturia. - Urinary retention due to BPH: facilitates bladder emptying and reduces the need for catheterisation.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially when standing quickly. - Headache: mild to moderate intensity. - Abnormal ejaculation: reduced volume or retrograde flow. - Nasal congestion: stuffiness or runny nose. - Orthostatic hypotension: drop in blood pressure upon standing. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure requiring medical attention. - Syncope: fainting episodes. - Priapism: prolonged, painful erection. - Allergic reaction: rash, itching, or swelling. - Angioedema: rapid swelling of face, lips, or throat. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy, consider the following precautions: - Renal impairment: monitor renal function and adjust therapy if needed. - Hypotension: assess blood pressure, especially during the first weeks of treatment. - Surgery: inform the surgical team, as the drug may cause intra‑operative hypotension. - Concomitant medications: review all current drugs for potential additive effects. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Tamsulosin may interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase tamsulosin plasma concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Other alpha‑blockers (e.g., doxazosin): additive risk of hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: enhanced hypotensive response, monitor blood pressure. - Warfarin: possible increase in INR, check coagulation parameters regularly.